Microbix partners with Angiogen for urokinase cancer treatment
"Having this facility and the urokinase technology allowed us to establish an exclusive relationship with Angiogen, the company that has a patented use of urokinase as they pursue indications in the treatment of cancers such as colorectal and prostate," said William J. Gastle, President and CEO of Microbix.
Financial activities required to complete Phase 1 and Phase 2 clinical trials are expected to conclude in 2007 after which the companies expect to complete the Phase 1 trial in 2008.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.